127 related articles for article (PubMed ID: 26339411)
1. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.
Bandala C; Cortés-Algara AL; Mejía-Barradas CM; Ilizaliturri-Flores I; Dominguez-Rubio R; Bazán-Méndez CI; Floriano-Sánchez E; Luna-Arias JP; Anaya-Ruiz M; Lara-Padilla E
Int J Clin Exp Pathol; 2015; 8(7):8411-8. PubMed ID: 26339411
[TBL] [Abstract][Full Text] [Related]
2. Synaptic vesicle protein 2 (SV2) isoforms.
Bandala C; Miliar-García A; Mejía-Barradas CM; Anaya-Ruiz M; Luna-Arias JP; Bazán-Méndez CI; Gómez-López M; Juárez-Méndez S; Lara-Padilla E
Asian Pac J Cancer Prev; 2012; 13(10):5063-7. PubMed ID: 23244111
[TBL] [Abstract][Full Text] [Related]
3. SV2 is the protein receptor for botulinum neurotoxin A.
Dong M; Yeh F; Tepp WH; Dean C; Johnson EA; Janz R; Chapman ER
Science; 2006 Apr; 312(5773):592-6. PubMed ID: 16543415
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic targeting of botulinum neurotoxin type A requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry.
Joensuu M; Syed P; Saber SH; Lanoue V; Wallis TP; Rae J; Blum A; Gormal RS; Small C; Sanders S; Jiang A; Mahrhold S; Krez N; Cousin MA; Cooper-White R; Cooper-White JJ; Collins BM; Parton RG; Balistreri G; Rummel A; Meunier FA
EMBO J; 2023 Jul; 42(13):e112095. PubMed ID: 37226896
[TBL] [Abstract][Full Text] [Related]
5. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.
Peng L; Tepp WH; Johnson EA; Dong M
PLoS Pathog; 2011 Mar; 7(3):e1002008. PubMed ID: 21483489
[TBL] [Abstract][Full Text] [Related]
6. [Botulinum toxin type-A toxin activity on prostate cancer cell lines].
Proietti S; Nardicchi V; Porena M; Giannantoni A
Urologia; 2012; 79(2):135-41. PubMed ID: 22610840
[TBL] [Abstract][Full Text] [Related]
7. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
[TBL] [Abstract][Full Text] [Related]
8. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
Rummel A; Häfner K; Mahrhold S; Darashchonak N; Holt M; Jahn R; Beermann S; Karnath T; Bigalke H; Binz T
J Neurochem; 2009 Sep; 110(6):1942-54. PubMed ID: 19650874
[TBL] [Abstract][Full Text] [Related]
9. Three players in the 'toxic affair' between botulinum neurotoxin type A and neurons.
Rossetto O; Pirazzini M; Montecucco C
Trends Neurosci; 2023 Sep; 46(9):695-697. PubMed ID: 37385877
[TBL] [Abstract][Full Text] [Related]
10. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.
Mahrhold S; Strotmeier J; Garcia-Rodriguez C; Lou J; Marks JD; Rummel A; Binz T
Biochem J; 2013 Jul; 453(1):37-47. PubMed ID: 23621114
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.
Benoit RM; Frey D; Hilbert M; Kevenaar JT; Wieser MM; Stirnimann CU; McMillan D; Ceska T; Lebon F; Jaussi R; Steinmetz MO; Schertler GF; Hoogenraad CC; Capitani G; Kammerer RA
Nature; 2014 Jan; 505(7481):108-11. PubMed ID: 24240280
[TBL] [Abstract][Full Text] [Related]
12. Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes.
Baldwin MR; Barbieri JT
Biochemistry; 2007 Mar; 46(11):3200-10. PubMed ID: 17311420
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.
Liu Z; Lee PG; Krez N; Lam KH; Liu H; Przykopanski A; Chen P; Yao G; Zhang S; Tremblay JM; Perry K; Shoemaker CB; Rummel A; Dong M; Jin R
Nat Commun; 2023 Apr; 14(1):2338. PubMed ID: 37095076
[TBL] [Abstract][Full Text] [Related]
14. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder.
Coelho A; Dinis P; Pinto R; Gorgal T; Silva C; Silva A; Silva J; Cruz CD; Cruz F; Avelino A
Eur Urol; 2010 May; 57(5):884-90. PubMed ID: 20044204
[TBL] [Abstract][Full Text] [Related]
15. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.
Strotmeier J; Mahrhold S; Krez N; Janzen C; Lou J; Marks JD; Binz T; Rummel A
FEBS Lett; 2014 Apr; 588(7):1087-93. PubMed ID: 24583011
[TBL] [Abstract][Full Text] [Related]
16. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.
Rummel A
Curr Top Microbiol Immunol; 2013; 364():61-90. PubMed ID: 23239349
[TBL] [Abstract][Full Text] [Related]
17. Light and electron microscopic analysis of synaptic development in Macaca monkey retina as detected by immunocytochemical labeling for the synaptic vesicle protein, SV2.
Okada M; Erickson A; Hendrickson A
J Comp Neurol; 1994 Jan; 339(4):535-58. PubMed ID: 8144745
[TBL] [Abstract][Full Text] [Related]
18. The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance.
Stout KA; Dunn AR; Hoffman C; Miller GW
ACS Chem Neurosci; 2019 Sep; 10(9):3927-3938. PubMed ID: 31394034
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into the interaction of botulinum neurotoxin a with its neuronal receptor SV2C.
Li X; Brunner C; Wu Y; Leka O; Schneider G; Kammerer RA
Toxicon; 2020 Feb; 175():36-43. PubMed ID: 31783045
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of synaptic vesicle protein 2 (SV2) isoforms.
Bajjalieh SM; Frantz GD; Weimann JM; McConnell SK; Scheller RH
J Neurosci; 1994 Sep; 14(9):5223-35. PubMed ID: 8083732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
